RIG-inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1

Cellular Signalling

Volumn 28, Issue 5, 2016, Pages 335-347

  Szabo, Attila ^a,b   Fekete, Tunde ^a   Koncz, Gabor ^a,b   Kumar, Brahma V ^a   Pazmandi, Kitti ^a   Foldvari, Zsofia ^a   Hegedus, Balazs ^c,d   Garay, Tamas ^c,d   Bacsi, Attila ^a,b   Rajnavolgyi, Eva ^a,b   Lanyi, Arpad ^a,b  

^a UNIVERSITY OF DEBRECEN   (Hungary)

^b SAPIENTIA HUNGARIAN UNIVERSITY OF TRANSYLVANIA   (Romania)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

BRAF; MAPK; Melanoma; MKP 1 DUSP1; Proliferation; RIG I

Indexed keywords

BETA INTERFERON; CASPASE 3; CASPASE 7; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLYCOGEN SYNTHASE KINASE 3ALPHA; GLYCOGEN SYNTHASE KINASE 3BETA; HEAT SHOCK PROTEIN 27; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN C JUN; RETINOIC ACID; RETINOIC ACID INDUCIBLE PROTEIN I; SMALL INTERFERING RNA; B RAF KINASE; BRAF PROTEIN, HUMAN; CYTOKINE; DDX58 PROTEIN, HUMAN; DUSP1 PROTEIN, HUMAN; IRF3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BRAF MUTANT MELANOMA CELL LINE; CANCER INHIBITION; CELL COUNTING; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MELANOMA CELL LINE; MOLECULAR DYNAMICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; WESTERN BLOTTING; CELL PROLIFERATION; ENZYMOLOGY; GENETICS; MELANOMA; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; DEAD BOX PROTEIN 58; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; INTERFERON REGULATORY FACTOR-3; MAP KINASE SIGNALING SYSTEM; MELANOMA; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTO-ONCOGENE PROTEINS B-RAF; TRETINOIN;

EID: 84957949117     PISSN: 08986568     EISSN: 18733913     Source Type: Journal    
DOI: 10.1016/j.cellsig.2016.01.012     Document Type: Article

References (43)

1. Sharma P., Wagner K., Wolchok J.D., Allison J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 2011, 11:805-812.
2. Flaherty K.T., Robert C., Hersey P., Nathan P., Garbe C., Milhem M., Demidov L.V., Hassel J.C., Rutkowski P., Mohr P., Dummer R., Trefzer U., Larkin J.M., Utikal J., Dreno B., Nyakas M., Middleton M.R., Becker J.C., Casey M., Sherman L.J., Wu F.S., Ouellet D., Martin A.M., Patel K., Schadendorf D., Group M.S. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 2012, 367:107-114.
3. A.S.K., Postow M.A. Current options and future directions in the systemic treatment of metastatic melanoma. J. Community Support. Oncol. 2014, 12:20-26.
4. Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity 2011, 34:637-650.
5. Szabo A., Rajnavolgyi E. Collaboration of Toll-like and RIG-I-like receptors in human dendritic cells: tRIGgering antiviral innate immune responses. Am. J. Clin. Exp. Immunol. 2013, 2:195-207.
6. Kawai T., Akira S. Toll-like receptor and RIG-I-like receptor signaling. Ann. N. Y. Acad. Sci. 2008, 1143:1-20.
7. Nestle F.O., Di Meglio P., Qin J.Z., Nickoloff B.J. Skin immune sentinels in health and disease. Nat. Rev. Immunol. 2009, 9:679-691.
8. Poeck H., Besch R., Maihoefer C., Renn M., Tormo D., Morskaya S.S., Kirschnek S., Gaffal E., Landsberg J., Hellmuth J., Schmidt A., Anz D., Bscheider M., Schwerd T., Berking C., Bourquin C., Kalinke U., Kremmer E., Kato H., Akira S., Meyers R., Hacker G., Neuenhahn M., Busch D., Ruland J., Rothenfusser S., Prinz M., Hornung V., Endres S., Tuting T., Hartmann G. 5[U+02B9]-Triphosphate-siRNA: turning gene silencing and Rig-activation against melanoma. Nat. Med. 2008, 14:1256-1263.
9. Besch R., Poeck H., Hohenauer T., Senft D., Hacker G., Berking C., Hornung V., Endres S., Ruzicka T., Rothenfusser S., Hartmann G. Proapoptotic signaling induced by RIG-and MDA-results in type I interferon-independent apoptosis in human melanoma cells. J. Clin. Invest. 2009, 119:2399-2411.
10. Pan M., Geng S., Xiao S., Ren J., Liu Y., Li X., Li Z., Peng Z. Apoptosis induced by synthetic retinoic acid CD437 on human melanoma A375 cells involves RIG-pathway. Arch. Dermatol. Res. 2009, 301:15-20.
11. Arthur J.S., Ley S.C. Mitogen-activated protein kinases in innate immunity. Nat. Rev. Immunol. 2013, 13:679-692.
12. Gurgis F.M., Ziaziaris W., Munoz L. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting. Mol. Pharmacol. 2014, 85:345-356.
13. Smalley K.S., Sondak V.K. Targeted therapy for melanoma: is double hitting a home run?. Nat. Rev. Clin. Oncol. 2013, 10:5-6.
14. Flach R.J., Bennett A.M. MAP kinase phosphatase-1-new player at the nexus between sarcopenia and metabolic disease. Aging 2010, 2:170-176.
15. Wellbrock C., Weisser C., Geissinger E., Troppmair J., Schartl M. Activation of p59(Fyn) leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J. Biol. Chem. 2002, 277:6443-6454.
16. Arbiser J.L. Activation of B-raf in non-malignant nevi predicts a novel tumor suppressor gene in melanoma (MAP kinase phosphatase). J. Investig. Dermatol. 2003, 121:xiv.
17. Kundu S., Fan K., Cao M., Lindner D.J., Tuthill R., Liu L., Gerson S., Borden E., Yi T. Tyrosine phosphatase inhibitor-sensitizes melanoma and colon cancer to biotherapeutics and chemotherapeutics. Mol. Cancer Ther. 2010, 9:2287-2296.
18. Szatmari I., Gogolak P., Im J.S., Dezso B., Rajnavolgyi E., Nagy L. Activation of PPARgamma specifies a dendritic cell subtype capable of enhanced induction of iNKT cell expansion. Immunity 2004, 21:95-106.
19. Kast R.E. Potential for all-trans retinoic acid (tretinoin) to enhance interferon-alpha treatment response in chronic myelogenous leukemia, melanoma, myeloma and renal cell carcinoma. Cancer Biol. Ther. 2008, 7:1515-1519.
20. Salaun B., Lebecque S., Matikainen S., Rimoldi D., Romero P. Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. Clin. Cancer Res. 2007, 13:4565-4574.
21. Hornung V., Ellegast J., Kim S., Brzozka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., Endres S., Hartmann G. 5[U+02B9]-Triphosphate RNA is the ligand for RIG-I. Science 2006, 314:994-997.
22. Gesser B., Rasmussen M.K., Raaby L., Rosada C., Johansen C., Kjellerup R.B., Kragballe K., Iversen L. Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflamm. Res. 2011, 60:643-653.
23. Shin S., Wolgamott L., Yu Y., Blenis J., Yoon S.O. Glycogen synthase kinase (GSK)-promotes p70 ribosomal protein S6 kinase (p70S6K) activity and cell proliferation. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:E1204-E1213.
24. Dent P. New methods to control neuroblastoma growth. Cancer Biol. Ther. 2014, 15:481-482.
25. Sims J.T., Ganguly S.S., Bennett H., Friend J.W., Tepe J., Plattner R. Imatinib reverses doxorubicin resistance by affecting activation of STAT3-dependent NF-kappaB and HSP27/p38/AKT pathways and by inhibiting ABCB1. PLoS One 2013, 8:e55509.
26. Kogushi-Nishi H., Jinnin M., Kobayashi Y., Muchemwa F.C., Hirano A., Makino T., Fukushima S., Masuguchi S., Ishihara T., Inoue Y., Ihn H. Role of c-Jun N-terminal kinase isoforms in the cellular activity of melanoma cell lines. Clin. Exp. Dermatol. 2013, 38:890-896.
27. Li S., Zhu F., Zykova T., Kim M.O., Cho Y.Y., Bode A.M., Peng C., Ma W., Carper A., Langfald A., Dong Z. T-LAK cell-originated protein kinase (TOPK) phosphorylation of MKP1 protein prevents solar ultraviolet light-induced inflammation through inhibition of the p38 protein signaling pathway. J. Biol. Chem. 2011, 286:29601-29609.
28. Kristiansen M., Hughes R., Patel P., Jacques T.S., Clark A.R., Ham J. Mkp1 is a c-Jun target gene that antagonizes JNK-dependent apoptosis in sympathetic neurons. J. Neurosci. 2010, 30:10820-10832.
29. Wang Z., Bildin V.N., Yang H., Capo-Aponte J.E., Yang Y., Reinach P.S. Dependence of corneal epithelial cell proliferation on modulation of interactions between ERK1/2 and NKCC1. Cell. Physiol. Biochem. 2011, 28:703-714.
30. Korhonen R., Moilanen E. Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. Basic Clin. Pharmacol. Toxicol. 2014, 114:24-36.
31. Landry J., Huot J. Modulation of actin dynamics during stress and physiological stimulation by a signaling pathway involving p38 MAP kinase and heat-shock protein 27. Biochem. Cell Biol. 1995, 73:703-707.
32. Beyaert R., Cuenda A., Vanden Berghe W., Plaisance S., Lee J.C., Haegeman G., Cohen P., Fiers W. The p38/RK mitogen-activated protein kinase pathway regulates interleukin-synthesis response to tumor necrosis factor. EMBO J. 1996, 15:1914-1923.
33. Eggermont A.M., Robert C. New drugs in melanoma: it's a whole new world. Eur. J. Cancer 2011, 47:2150-2157.
34. Sanlorenzo M., Vujic I., Posch C., Dajee A., Yen A., Kim S., Ashworth M., Rosenblum M.D., Algazi A., Osella-Abate S., Quaglino P., Daud A., Ortiz-Urda S. Melanoma immunotherapy. Cancer Biol. Ther. 2014, 15:665-674.
35. Roman R.A. Immunotherapy for advanced melanoma. Clin. J. Oncol. Nurs. 2011, 15:E58-E65.
36. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012, 12:125-135.
37. Caraglia M., Marra M., Tagliaferri P., Lamberts S.W., Zappavigna S., Misso G., Cavagnini F., Facchini G., Abbruzzese A., Hofland L.J., Vitale G. Emerging strategies to strengthen the anti-tumour activity of type I interferons: overcoming survival pathways. Curr. Cancer Drug Targets 2009, 9:690-704.
38. Yang X., Zhang X., Fu M.L., Weichselbaum R.R., Gajewski T.F., Guo Y., Fu Y.X. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell 2014, 25:37-48.
39. Mobley A.K., Braeuer R.R., Kamiya T., Shoshan E., Bar-Eli M. Driving transcriptional regulators in melanoma metastasis. Cancer Metastasis Rev. 2012, 31:621-632.
40. Madonna G., Ullman C.D., Gentilcore G., Palmieri G., Ascierto P.A. NF-kappaB as potential target in the treatment of melanoma. J. Transl. Med. 2012, 10:53.
41. He R.J., Yu Z.H., Zhang R.Y., Zhang Z.Y. Protein tyrosine phosphatases as potential therapeutic targets. Acta Pharmacol. Sin. 2014, 35:1227-1246.
42. Huen A.O., Rook A.H. Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr. Opin. Oncol. 2014, 26:237-244.
43. Boone B.A., Lotze M.T. Targeting damage-associated molecular pattern molecules (DAMPs) and DAMP receptors in melanoma. Methods Mol. Biol. 2014, 1102:537-552.